

O I P E
JAN 8 7 2002
PATENT & TRADEMARK OFFICE 1434
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-325200US
Client Ref. No.: E-157-97/2

Assistant Commissioner for Patents
Washington, D.C. 20231

On 13 Nov. 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Malinda Doig

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Susanna M. Rybak, Dianne L.
Newton and David M. Goldenberg

Application No.: 09/918,887

Filed: July 30, 2001

For: IMMUNOTOXINS DIRECTED
AGAINST MALIGNANT CELLS

Art Unit: 1614

**RESPONSE TO REQUEST FOR
SUBSTITUTE DRAWINGS**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to File Corrected Application Papers mailed September 13, 2001, Applicants submit the required substitute drawings.

Applicants respectfully request replacement of Figures 1-9 (sheets 1-9) with the Substitute Sheets 1-9 submitted herewith.

Fig. 3 (Sheet 3/9) has been amended to change the symbol and line designations as shown on the marked up copy of Figure 3 submitted herewith. This amendment adds no new matter and merely improves readability of Fig. 3.

Fig. 9 (Sheet 9/9) has been amended to delete the title and to delete the reference in the last line as set forth on the marked up copy of Figure 9. This amendment adds no new matter.

Figure 3

FIG. 3.





Figure 9

Toxicity of LL2-Onc vs Onc or IT-dgRTA to Mice



Drugs administered every 2 h
4x/day for 5 days. The arrows
indicate the days the mice with
each respective treatment were
found dead

REF4-PE35KDEL, 1 x/day for 4 days; LD50 1 mg/kg
E. Mansfield et al., Bioconjugate Chem. 1998, 9, 557